Papadopoulos, K. P., Owonikoko, T. K., Johnson, M. L., Brana, I., Gil-Martin, M., Perez, R. P., Moreno, V., Salama, A. K., Calvo, E., Yee, N. S., Safran, H., Gonzalez-Martin, A., Aljumaily, R., Mahadevan, D., Mohan, K. K., Li, J., Stankevich, E., Lowy, I., Fury, M. G. and Homsi, J. (2018) “Cemiplimab (REGN2810), a Fully Human Anti-PD-1 Monoclonal Antibody, for Patients with Unresectable Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma: Initial Safety and Efficacy from Expansion Cohorts of Phase 1 Study”, SKIN The Journal of Cutaneous Medicine, 2(S1), p. S45. doi: 10.25251/skin.2.supp.45.